{"id":"norepinephrine","rwe":[{"pmid":"41906544","year":"2026","title":"Understanding Atomoxetine Exposure Variability in Children and Adolescents With ADHD Through Population Pharmacokinetics.","finding":"","journal":"Journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"41905899","year":"2026","title":"Emerging mechanisms of ILC2-neuronal crosstalk across the body.","finding":"","journal":"Immunology and cell biology","studyType":"Clinical Study"},{"pmid":"41905254","year":"2026","title":"Stress and sleep: Novel insights into stress-related sleep disorders from EEG features to neural circuitry.","finding":"","journal":"Sleep medicine","studyType":"Clinical Study"},{"pmid":"41904178","year":"2026","title":"Human narcolepsy is linked to degeneration of both locus coeruleus and hypocretin neurons.","finding":"","journal":"Nature communications","studyType":"Clinical Study"},{"pmid":"41903111","year":"2026","title":"Mechanisms of norepinephrine induced Ca(2+) responses in perivascular adipose tissue.","finding":"","journal":"American journal of physiology. Endocrinology and metabolism","studyType":"Clinical Study"}],"_fda":{"id":"240616bf-5277-ae18-dc3d-738f3bbabb55","set_id":"0ea48ab6-e166-df31-b132-70ef982a2d02","openfda":{"unii":["IFY5PE3ZRW"],"route":["INTRAVENOUS"],"rxcui":["242969"],"spl_id":["240616bf-5277-ae18-dc3d-738f3bbabb55"],"brand_name":["NOREPINEPHRINE BITARTRATE"],"spl_set_id":["0ea48ab6-e166-df31-b132-70ef982a2d02"],"package_ndc":["70377-121-11","70377-121-12"],"product_ndc":["70377-121"],"generic_name":["NOREPINEPHRINE BITARTRATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["NOREPINEPHRINE BITARTRATE"],"manufacturer_name":["BIOCON PHARMA INC."],"application_number":["ANDA219443"],"is_original_packager":[true]},"version":"3","pregnancy":["8.1 Pregnancy Risk Summary Limited published data consisting of a small number of case reports and multiple small trials involving the use of norepinephrine in pregnant women at the time of delivery have not identified an increased risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus from hypotension associated with septic shock, myocardial infarction and stroke which are medical emergencies in pregnancy and can be fatal if left untreated. ( see Clinical Considerations ). In animal reproduction studies, using high doses of intravenous norepinephrine resulted in lowered maternal placental blood flow. Clinical relevance to changes in the human fetus is unknown since the average maintenance dose is ten times lower ( see Data ). Increased fetal reabsorptions were observed in pregnant hamsters after receiving daily injections at approximately 2 times the maximum recommended dose on a mg/m 3 basis for four days during organogenesis ( see Data ). The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypotension associated with septic shock, myocardial infarction, and stroke are medical emergencies in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic shock, myocardial infarction and stroke may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of norepinephrine on the fetus. Data Animal Data A study in pregnant sheep receiving high doses of intravenous norepinephrine (40 mcg/min, at approximately 10 times the average maintenance dose of 2 to 4 mcg/min in human, on a mg/kg basis) exhibited a significant decrease in maternal placental blood flow. Decreases in fetal oxygenation, urine and lung liquid flow were also observed. Norepinephrine administration to pregnant rats on Gestation Day 16 or 17 resulted in cataract production in rat fetuses. In hamsters, an increased number of resorptions (29.1% in study group vs. 3.4% in control group), fetal microscopic liver abnormalities and delayed skeletal ossification were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day from Gestation Day 7 to 10)."],"overdosage":["10 OVERDOSAGE Overdosage with norepinephrine bitartrate may result in headache, severe hypertension, reflex bradycardia, marked increase in peripheral resistance, and decreased cardiac output. In case of overdosage, discontinue norepinephrine bitartrate until the condition of the patient stabilizes."],"description":["11 DESCRIPTION Norepinephrine (sometimes referred to as l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic amine which differs from epinephrine by the absence of a methyl group on the nitrogen atom. Norepinephrine bitartrate, USP is (-)-α-(aminomethyl)-3,4-dihydroxybenzyl alcohol tartrate (1:1) (salt), monohydrate (molecular weight 337.28 g/mol) and has the following structural formula: Norepinephrine bitartrate injection, USP is supplied in a sterile aqueous solution in the form of the bitartrate salt to be administered by intravenous infusion. Norepinephrine is freely soluble in purified water slightly soluble in alcohol, practically insoluble in chloroform and ether. Each mL contains 1 mg of norepinephrine base (equivalent to 1.89 mg of norepinephrine bitartrate, USP anhydrous basis), sodium chloride for isotonicity, not more than 0.2 mg (vials) of sodium metabisulfite as an antioxidant. It has a pH of 3.0 to 4.5. The air in the containers has been displaced by nitrogen gas. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Norepinephrine Bitartrate injection, USP, is a sterile, clear, colorless to slightly yellow solution for injection intended for intravenous use. It contains the equivalent of 1 mg of norepinephrine base per 1 mL (4 mg/4 mL). It is available as 4 mg/4 mL in single-dose amber glass vials Supplied as: Unit of Sale Concentration NDC 70377-121-12 10 vials in a Carton 4 mg/4 mL (1 mg/mL) Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature]. Store in original carton until time of administration to protect from light. Discard unused portion."],"geriatric_use":["8.5 Geriatric Use Clinical studies of norepinephrine bitartrate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Avoid administration of norepinephrine bitartrate into the veins in the leg in elderly patients [see Warnings and Precautions (5.1) ] ."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20250617","pharmacodynamics":["12.2 Pharmacodynamics The primary pharmacodynamic effects of norepinephrine are cardiac stimulation and vasoconstriction. Cardiac output is generally unaffected, although it can be decreased, and total peripheral resistance is also elevated. The elevation in resistance and pressure result in reflex vagal activity, which slows the heart rate and increases stroke volume. The elevation in vascular tone or resistance reduces blood flow to the major abdominal organs as well as to skeletal muscle. Coronary blood flow is substantially increased secondary to the indirect effects of alpha stimulation. After intravenous administration, a pressor response occurs rapidly and reaches steady state within 5 minutes. The pharmacologic actions of norepinephrine are terminated primarily by uptake and metabolism in sympathetic nerve endings. The pressor action stops within 1-2 minutes after the infusion is discontinued."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Following initiation of intravenous infusion, the steady state plasma concentration is achieved in 5 min. Distribution Plasma protein binding of norepinephrine is approximately 25%. It is mainly bound to plasma albumin and to a smaller extent to prealbumin and alpha 1-acid glycoprotein. The volume of distribution is 8.8 L. Norepinephrine localizes mainly in sympathetic nervous tissue. It crosses the placenta but not the blood-brain barrier. Elimination The mean half-life of norepinephrine is approximately 2.4 min. The average metabolic clearance is 3.1 L/min. Metabolism Norepinephrine is metabolized in the liver and other tissues by a combination of reactions involving the enzymes catechol-O-methyltransferase (COMT) and MAO. The major metabolites are normetanephrine and 3- methoxyl-4-hydroxy mandelic acid (vanillylmandelic acid, VMA), both of which are inactive. Other inactive metabolites include 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxymandelic acid, and 3,4- dihydroxyphenylglycol. Excretion Noradrenaline metabolites are excreted in urine primarily as sulphate conjugates and, to a lesser extent, as glucuronide conjugates. Only small quantities of norepinephrine are excreted unchanged."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are described in greater detail in other sections: Tissue Ischemia [see Warnings and Precautions (5.1) ] Hypotension [see Warnings and Precautions (5.2) ] Cardiac Arrhythmias [see Warnings and Precautions (5.3) ] The most common adverse reactions are hypertension and bradycardia. The following adverse reactions can occur: Nervous system disorders: Anxiety, headache Respiratory disorders: Respiratory difficulty, pulmonary edema Most common adverse reactions are ischemic injury, bradycardia, anxiety, transient headache, respiratory difficulty, and extravasation necrosis at injection site. (6) To report SUSPECTED ADVERSE REACTIONS, contact Biocon Pharma Inc., at 1-866-924-6266 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. ( 7.1 ) Cyclopropane and halothane anesthetics increase cardiac autonomic irritability. ( 7.4 ) 7.1 MAO-Inhibiting Drugs Co-administration of norepinephrine bitartrate with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of norepinephrine bitartrate cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of norepinephrine bitartrate with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If administration of norepinephrine bitartrate cannot be avoided in these patients, monitor for hypertension. 7.3 Antidiabetics Norepinephrine bitartrate can decrease insulin sensitivity and raise blood glucose. Monitor glucose and consider dosage adjustment of antidiabetic drugs. 7.4 Halogenated Anesthetics Concomitant use of norepinephrine bitartrate with halogenated anesthetics (e.g., cyclopropane, desflurane, enflurane, isoflurane, and sevoflurane) may lead to ventricular tachycardia or ventricular fibrillation. Monitor cardiac rhythm in patients receiving concomitant halogenated anesthetics."],"how_supplied_table":["<table><col/><col/><tbody><tr><td valign=\"top\"><content styleCode=\"bold\">Unit of Sale</content></td><td valign=\"top\"><content styleCode=\"bold\">Concentration</content></td></tr><tr><td valign=\"top\"><paragraph><content styleCode=\"bold\">NDC 70377-121-12</content></paragraph><paragraph>10 vials in a Carton</paragraph></td><td valign=\"top\"><paragraph>4 mg/4 mL</paragraph><paragraph>(1 mg/mL)</paragraph></td></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action)."],"storage_and_handling":["Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature]. Store in original carton until time of administration to protect from light. Discard unused portion."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). 12.2 Pharmacodynamics The primary pharmacodynamic effects of norepinephrine are cardiac stimulation and vasoconstriction. Cardiac output is generally unaffected, although it can be decreased, and total peripheral resistance is also elevated. The elevation in resistance and pressure result in reflex vagal activity, which slows the heart rate and increases stroke volume. The elevation in vascular tone or resistance reduces blood flow to the major abdominal organs as well as to skeletal muscle. Coronary blood flow is substantially increased secondary to the indirect effects of alpha stimulation. After intravenous administration, a pressor response occurs rapidly and reaches steady state within 5 minutes. The pharmacologic actions of norepinephrine are terminated primarily by uptake and metabolism in sympathetic nerve endings. The pressor action stops within 1-2 minutes after the infusion is discontinued. 12.3 Pharmacokinetics Absorption Following initiation of intravenous infusion, the steady state plasma concentration is achieved in 5 min. Distribution Plasma protein binding of norepinephrine is approximately 25%. It is mainly bound to plasma albumin and to a smaller extent to prealbumin and alpha 1-acid glycoprotein. The volume of distribution is 8.8 L. Norepinephrine localizes mainly in sympathetic nervous tissue. It crosses the placenta but not the blood-brain barrier. Elimination The mean half-life of norepinephrine is approximately 2.4 min. The average metabolic clearance is 3.1 L/min. Metabolism Norepinephrine is metabolized in the liver and other tissues by a combination of reactions involving the enzymes catechol-O-methyltransferase (COMT) and MAO. The major metabolites are normetanephrine and 3- methoxyl-4-hydroxy mandelic acid (vanillylmandelic acid, VMA), both of which are inactive. Other inactive metabolites include 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxymandelic acid, and 3,4- dihydroxyphenylglycol. Excretion Noradrenaline metabolites are excreted in urine primarily as sulphate conjugates and, to a lesser extent, as glucuronide conjugates. Only small quantities of norepinephrine are excreted unchanged."],"indications_and_usage":["1 INDICATIONS AND USAGE Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with severe, acute hypotension. Norepinephrine bitartrate injection is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Tissue Ischemia : Avoid extravasation of norepinephrine bitartrate injection into the tissues, as local necrosis might ensue due to the vasoconstrictive action of the drug. Infuse norepinephrine bitartrate injection into a large vein. To prevent sloughing and necrosis in areas in which extravasation has taken place, the area should be infiltrated as soon as possible with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of an adrenergic blocking agent. ( 5.1 ) Hypotension After Abrupt Discontinuation : Sudden cessation of the infusion rate may result in marked hypotension. Reduce the norepinephrine bitartrate injection infusion rate gradually. ( 5.2 ) Cardiac Arrhythmias: Norepinephrine bitartrate injection may cause arrhythmias. Monitor cardiac function in patients with underlying heart disease. ( 5.3 ) Allergic Reactions with Sulfite: Norepinephrine bitartrate injection contains sodium metabisulfite. Sulfite may cause allergic-type-reactions. ( 5.4 ) 5.1 Tissue Ischemia Administration of norepinephrine bitartrate to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite “normal” blood pressure. Address hypovolemia prior to initiating norepinephrine bitartrate [see Dosage and Administration (2.1) ]. Avoid norepinephrine bitartrate in patients with mesenteric or peripheral vascular thrombosis, as this may increase ischemia and extend the area of infarction. Gangrene of the extremities has occurred in patients with occlusive or thrombotic vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients. Extravasation of norepinephrine bitartrate may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein, check the infusion site frequently for free flow, and monitor for signs of extravasation [see Dosage and Administration (2.1) ]. Emergency Treatment of Extravasation To prevent sloughing and necrosis in areas in which extravasation has occurred, infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with 5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. 5.2 Hypotension after Abrupt Discontinuation Sudden cessation of the infusion rate may result in marked hypotension. When discontinuing the infusion, gradually reduce the norepinephrine bitartrate infusion rate while expanding blood volume with intravenous fluids. 5.3 Cardiac Arrhythmias Norepinephrine bitartrate elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the setting of hypoxia or hypercarbia. Perform continuous cardiac monitoring of patients with arrhythmias. 5.4 Allergic Reactions Associated with Sulfite Norepinephrine bitartrate injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis, mutagenesis, and fertility studies have not been performed."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient, family, or caregiver to report signs of extravasation urgently [see Warnings and Precautions (5.1)]. Manufactured by: Immacule Lifesciences Pvt. Ltd. HP, India-174 101 Manufactured for: Biocon Pharma Inc., Iselin, New Jersey, 08830-3009 United States of America"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Initial dose of 0.25 mL to 0.375 mL (from 8 mcg to 12 mcg of base) per minute, adjust the rate of flow to establish and maintain a low to normal blood pressure (usually 80 mm Hg to 100 mm Hg systolic) sufficient to maintain the circulation of vital organs. ( 2.2 ) The average maintenance dose ranges from 0.0625 mL to 0.125 mL per minute (from 2 mcg to 4 mcg of base). ( 2.2 ) 2.1 Important Dosage and Administration Instructions Correct Hypovolemia Address hypovolemia before initiation of norepinephrine bitartrate injection therapy. If the patient does not respond to therapy, suspect occult hypovolemia [see Warnings and Precautions (5.1) ] . Administration Dilute norepinephrine bitartrate injection prior to use [see Dosage and Administration (2.3) ] . Infuse norepinephrine bitartrate injection into a large vein. Avoid infusions into the veins of the leg in the elderly or in patients with occlusive vascular disease of the legs [see Warnings and Precautions (5.1) ]. Avoid using a catheter-tie-in technique . Discontinuation When discontinuing the infusion, reduce the flow rate gradually. Avoid abrupt withdrawal. 2.2 Dosage After an initial dosage of 8 to 12 mcg per minute via intravenous infusion, assess patient response and adjust dosage to maintain desired hemodynamic effect. Monitor blood pressure every two minutes until the desired hemodynamic effect is achieved, and then monitor blood pressure every five minutes for the duration of the infusion. Typical maintenance intravenous dosage is 2 to 4 mcg per minute. 2.3 Preparation of Diluted Solution Visually inspect norepinephrine bitartrate injection for particulate matter and discoloration prior to administration (the solution is colorless). Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate. Add the content of one norepinephrine bitartrate injection vial (4 mg in 4 mL) to 1,000 mL of 5% Dextrose Injection, USP or Sodium Chloride Injection solutions that contain 5% dextrose to produce a 4 mcg per mL dilution. Dextrose reduces loss of potency due to oxidation. Administration in saline solution alone is not recommended. Use higher concentration solutions in patients requiring fluid restriction. Prior to use, store the diluted norepinephrine bitartrate injection solution for up to 24 hours at room temperature [20°C to 25°C (68°F to 77°F)] and protect from light. 2.4 Drug Incompatibilities Avoid contact with iron salts, alkalis, or oxidizing agents. Whole blood or plasma, if indicated to increase blood volume, should be administered separately."],"spl_product_data_elements":["NOREPINEPHRINE BITARTRATE NOREPINEPHRINE BITARTRATE NOREPINEPHRINE BITARTRATE NOREPINEPHRINE SODIUM CHLORIDE SODIUM METABISULFITE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 4 mg/4 mL (1 mg/mL norepinephrine base) sterile, clear, colorless to slightly yellow solution in a single-dose amber glass vial. Injection: 4 mg/4 mL (1 mg/mL) norepinephrine base in single-dose glass vial. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Elderly patients may be at greater risk of developing adverse reactions. ( 8.5 ) 8.1 Pregnancy Risk Summary Limited published data consisting of a small number of case reports and multiple small trials involving the use of norepinephrine in pregnant women at the time of delivery have not identified an increased risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus from hypotension associated with septic shock, myocardial infarction and stroke which are medical emergencies in pregnancy and can be fatal if left untreated. ( see Clinical Considerations ). In animal reproduction studies, using high doses of intravenous norepinephrine resulted in lowered maternal placental blood flow. Clinical relevance to changes in the human fetus is unknown since the average maintenance dose is ten times lower ( see Data ). Increased fetal reabsorptions were observed in pregnant hamsters after receiving daily injections at approximately 2 times the maximum recommended dose on a mg/m 3 basis for four days during organogenesis ( see Data ). The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypotension associated with septic shock, myocardial infarction, and stroke are medical emergencies in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic shock, myocardial infarction and stroke may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of norepinephrine on the fetus. Data Animal Data A study in pregnant sheep receiving high doses of intravenous norepinephrine (40 mcg/min, at approximately 10 times the average maintenance dose of 2 to 4 mcg/min in human, on a mg/kg basis) exhibited a significant decrease in maternal placental blood flow. Decreases in fetal oxygenation, urine and lung liquid flow were also observed. Norepinephrine administration to pregnant rats on Gestation Day 16 or 17 resulted in cataract production in rat fetuses. In hamsters, an increased number of resorptions (29.1% in study group vs. 3.4% in control group), fetal microscopic liver abnormalities and delayed skeletal ossification were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day from Gestation Day 7 to 10). 8.2 Lactation Risk Summary There are no data on the presence of norepinephrine in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. Clinically relevant exposure to the infant is not expected based on the short half-life and poor oral bioavailability of norepinephrine. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of norepinephrine bitartrate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Avoid administration of norepinephrine bitartrate into the veins in the leg in elderly patients [see Warnings and Precautions (5.1) ] ."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 4 mL Vial Label vial-label - 4 mL Vial Label","PRINCIPAL DISPLAY PANEL - 4 mL Vial Carton PRINCIPAL DISPLAY PANEL - 4 mL Vial Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis, mutagenesis, and fertility studies have not been performed."]},"tags":[{"label":"Catecholamine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-1D adrenergic receptor","category":"target"},{"label":"ADRA1D","category":"gene"},{"label":"ADRA2C","category":"gene"},{"label":"ADRA2A","category":"gene"},{"label":"C01CA03","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Acute exacerbation of asthma","category":"indication"},{"label":"Asthma","category":"indication"},{"label":"Asthma management","category":"indication"},{"label":"Bronchiectasis","category":"indication"},{"label":"Bronchitis","category":"indication"},{"label":"Low blood pressure","category":"indication"},{"label":"Hospira","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic alpha-Agonists","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sympathomimetics","category":"pharmacology"},{"label":"Vasoconstrictor Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"2743 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"1392 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1270 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"893 reports"},{"date":"","signal":"MULTIPLE ORGAN DYSFUNCTION SYNDROME","source":"FDA FAERS","actionTaken":"804 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"790 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"779 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"731 reports"},{"date":"","signal":"TOXICITY TO VARIOUS AGENTS","source":"FDA FAERS","actionTaken":"708 reports"},{"date":"","signal":"CARDIAC ARREST","source":"FDA FAERS","actionTaken":"700 reports"}],"drugInteractions":[{"url":"/drug/inhalational-anesthetics","drug":"Inhalational Anesthetics","action":"Use caution","effect":"Inhalational Anesthetics may enhance the arrhythmogenic effect of Alpha/Beta Agonists","source":"DrugCentral","drugSlug":"inhalational-anesthetics"},{"url":"/drug/isocarboxazid","drug":"isocarboxazid","action":"Avoid combination","effect":"May interact with Isocarboxazid","source":"DrugCentral","drugSlug":"isocarboxazid"},{"url":"/drug/methylthioninium-chloride","drug":"methylthioninium chloride","action":"Avoid combination","effect":"May interact with Methylene Blue","source":"DrugCentral","drugSlug":"methylthioninium-chloride"},{"url":"/drug/phenelzine","drug":"phenelzine","action":"Avoid combination","effect":"May interact with Phenelzine","source":"DrugCentral","drugSlug":"phenelzine"},{"url":"/drug/procarbazine","drug":"procarbazine","action":"Avoid combination","effect":"May interact with Procarbazine","source":"DrugCentral","drugSlug":"procarbazine"},{"url":"/drug/tranylcypromine","drug":"tranylcypromine","action":"Avoid combination","effect":"May interact with Tranylcypromine","source":"DrugCentral","drugSlug":"tranylcypromine"}],"commonSideEffects":[{"effect":"Multiple organ dysfunction syndrome","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Cardiogenic shock","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Septic shock","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Cardiac arrest","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Appendicolith","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypotension","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Metabolic acidosis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Acute kidney injury","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Ventricular fibrillation","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Fatigue","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Appendicitis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Sepsis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Respiratory failure","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["Hypercapnia","Hypertensive disorder","Hypovolemia","Hypoxia","Occlusive Vascular Disease","Thrombosis"],"specialPopulations":{"Pregnancy":"Animal reproduction studies have not been conducted with LEVOPHED. It is also not known whether LEVOPHED can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. LEVOPHED should be given to pregnant woman only if clearly needed.","Geriatric use":"Clinical studies of norepinephrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.","Paediatric use":"Safety and effectiveness in pediatric patients has not been established.","Hepatic impairment":"In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function."}},"trials":[],"aliases":["noradrenaline"],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NOREPINEPHRINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:59:38.220477+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:59:45.031498+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T02:59:36.841079+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NOREPINEPHRINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:59:45.772605+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:59:35.781495+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:59:35.781549+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T02:59:47.380046+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:59:56.990762+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL432/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:59:46.308688+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following adverse reactions are described in greater detail in other sections: Tissue Ischemia [see Warnings and Precautions (5.1) ] Hypotension [see Warnings and Precautions (5.2) ] Cardiac Arrhythmias [see Warnings and Precautions (5.3) ] The most common adverse reactions are hypertension and bradycardia. The following adverse reactions can occur: Nervous system disorders: Anxiety, headache Respiratory disorders: Respiratory difficulty, pulmonary edema Most common adver","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:59:59.698877+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA219443","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:59:35.781559+00:00"}},"allNames":"norepinephrine bitartrate in 5% dextrose","offLabel":[],"synonyms":["norepinephrine","(R)-Norepinephrine","arterenol","levarterenol","noradrenaline","norepinephrine bitartrate","(-)-noradrenaline"],"timeline":[{"date":"1950-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from HOSPIRA to Hospira"},{"date":"1950-07-13","type":"positive","source":"DrugCentral","milestone":"FDA approval (Hospira)"},{"date":"2022-10-06","type":"positive","source":"FDA Orange Book","milestone":"Norepinephrine Bitartrate In 0.9% Sodium Chloride approved — EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)"},{"date":"2025-08-11","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 17 manufacturers approved"},{"date":"2025-10-15","type":"positive","source":"FDA Orange Book","milestone":"Norepinephrine Bitartrate In 0.9% Sodium Chloride approved — EQ 32MG BASE/250ML (EQ 128MCG BASE/ML)"},{"date":"2026-02-06","type":"positive","source":"FDA Orange Book","milestone":"Norepinephrine Bitartrate In 0.9% Sodium Chloride approved — EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)"}],"approvals":[{"date":"1950-07-13","orphan":false,"company":"HOSPIRA","regulator":"FDA"}],"brandName":"Norepinephrine Bitartrate In 5% Dextrose","ecosystem":[{"indication":"Acute exacerbation of asthma","otherDrugs":[{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"epinephrine","slug":"epinephrine","company":""},{"name":"levosalbutamol","slug":"levosalbutamol","company":"Oak Pharms Inc"},{"name":"orciprenaline","slug":"orciprenaline","company":""}],"globalPrevalence":262000000},{"indication":"Asthma","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"}],"globalPrevalence":262000000},{"indication":"Asthma management","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"budesonide","slug":"budesonide","company":""},{"name":"ciclesonide","slug":"ciclesonide","company":"Takeda Gmbh"}],"globalPrevalence":262000000},{"indication":"Bronchiectasis","otherDrugs":[{"name":"acetylcysteine","slug":"acetylcysteine","company":"Apothecon"},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"cysteine","slug":"cysteine","company":"Hospira"},{"name":"epinephrine","slug":"epinephrine","company":""}],"globalPrevalence":null},{"indication":"Bronchitis","otherDrugs":[{"name":"acetylcysteine","slug":"acetylcysteine","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":null},{"indication":"Low blood pressure","otherDrugs":[{"name":"dopamine","slug":"dopamine","company":""},{"name":"epinephrine","slug":"epinephrine","company":""},{"name":"mephentermine","slug":"mephentermine","company":"Baxter Hlthcare Corp"},{"name":"metaraminol","slug":"metaraminol","company":""}],"globalPrevalence":null},{"indication":"Pulmonary emphysema","otherDrugs":[{"name":"arformoterol","slug":"arformoterol","company":"Sunovion"},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"diprophylline","slug":"diprophylline","company":""},{"name":"epinephrine","slug":"epinephrine","company":""}],"globalPrevalence":null}],"mechanism":{"target":"alpha-adrenergic receptors, beta-adrenergic receptors","novelty":"Follow-on","targets":[{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"ADRB1","source":"DrugCentral","target":"Beta-1 adrenergic receptor","protein":"Beta-1 adrenergic receptor"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"ADRB2","source":"DrugCentral","target":"Beta-2 adrenergic receptor","protein":"Beta-2 adrenergic receptor"},{"gene":"ADRB3","source":"DrugCentral","target":"Beta-3 adrenergic receptor","protein":"Beta-3 adrenergic receptor"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"}],"modality":"Small Molecule","drugClass":"Catecholamine","explanation":"Norepinephrine works by constricting peripheral blood vessels through alpha-adrenergic action, which increases blood pressure. It also stimulates the heart and dilates coronary arteries through beta-adrenergic action, enhancing cardiac output.","oneSentence":"Norepinephrine constricts blood vessels and stimulates the heart.","technicalDetail":"Norepinephrine binds to alpha-adrenergic receptors, causing vasoconstriction, and to beta-adrenergic receptors, leading to increased inotropy and coronary artery dilation."},"commercial":{"launchDate":"1950","_launchSource":"DrugCentral (FDA 1950-07-13, HOSPIRA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1960","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NOREPINEPHRINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NOREPINEPHRINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T13:01:18.644648","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:00:02.526212+00:00","fieldsConflicting":13,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"isoprenaline","drugSlug":"isoprenaline","fdaApproval":"1956-03-09","relationship":"same-class"},{"drugName":"dopamine","drugSlug":"dopamine","fdaApproval":"1974-02-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"phenylephrine","drugSlug":"phenylephrine","fdaApproval":"1952-01-21","patentExpiry":"Sep 26, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dobutamine","drugSlug":"dobutamine","fdaApproval":"1978-07-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"metaraminol","drugSlug":"metaraminol","fdaApproval":"1954-09-29","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methoxamine","drugSlug":"methoxamine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mephentermine","drugSlug":"mephentermine","fdaApproval":"1951-12-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"midodrine","drugSlug":"midodrine","fdaApproval":"1996-09-06","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenoldopam","drugSlug":"fenoldopam","fdaApproval":"1997-09-23","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"arbutamine","drugSlug":"arbutamine","fdaApproval":"1997-09-12","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"epinephrine","drugSlug":"epinephrine","fdaApproval":"1948-11-19","patentExpiry":"Oct 20, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"droxidopa","drugSlug":"droxidopa","fdaApproval":"2014-02-18","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"norepinephrine","indications":{"approved":[{"name":"Acute exacerbation of asthma","source":"DrugCentral","snomedId":708038006,"regulator":"FDA","eligibility":"Adults and children ≥ 12 years old","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Asthma","source":"DrugCentral","snomedId":195967001,"regulator":"FDA","eligibility":"Adults and children ≥ 12 years old","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Asthma management","source":"DrugCentral","snomedId":406162001,"regulator":"FDA","eligibility":"Adults and children ≥ 12 years old","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Bronchiectasis","source":"DrugCentral","snomedId":12295008,"regulator":"FDA","eligibility":"Adults and children ≥ 12 years old"},{"name":"Bronchitis","source":"DrugCentral","snomedId":32398004,"regulator":"FDA","eligibility":"Adults and children ≥ 12 years old"},{"name":"Low blood pressure","source":"DrugCentral","snomedId":45007003,"regulator":"FDA","eligibility":"Adults and children ≥ 12 years old"},{"name":"Pulmonary emphysema","source":"DrugCentral","snomedId":87433001,"regulator":"FDA","eligibility":"Adults and children ≥ 12 years old"}],"offLabel":[],"pipeline":[]},"currentOwner":"Hospira","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"isoprenaline","brandName":"isoprenaline","genericName":"isoprenaline","approvalYear":"1956","relationship":"same-class"},{"drugId":"dopamine","brandName":"dopamine","genericName":"dopamine","approvalYear":"1974","relationship":"same-class"},{"drugId":"phenylephrine","brandName":"phenylephrine","genericName":"phenylephrine","approvalYear":"1952","relationship":"same-class"},{"drugId":"dobutamine","brandName":"dobutamine","genericName":"dobutamine","approvalYear":"1978","relationship":"same-class"},{"drugId":"metaraminol","brandName":"metaraminol","genericName":"metaraminol","approvalYear":"1954","relationship":"same-class"},{"drugId":"methoxamine","brandName":"methoxamine","genericName":"methoxamine","approvalYear":"","relationship":"same-class"},{"drugId":"mephentermine","brandName":"mephentermine","genericName":"mephentermine","approvalYear":"1951","relationship":"same-class"},{"drugId":"midodrine","brandName":"midodrine","genericName":"midodrine","approvalYear":"1996","relationship":"same-class"},{"drugId":"fenoldopam","brandName":"fenoldopam","genericName":"fenoldopam","approvalYear":"1997","relationship":"same-class"},{"drugId":"arbutamine","brandName":"arbutamine","genericName":"arbutamine","approvalYear":"1997","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05168462","phase":"PHASE4","title":"Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-10-01","conditions":["Cardiogenic Shock","Myocardial Infarction"],"enrollment":776,"completionDate":"2028-04-01"},{"nctId":"NCT03648905","phase":"","title":"Clinical Laboratory Evaluation of Chronic Autonomic Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-09-06","conditions":["Parkinson's Disease","Multiple System Atrophy","Autonomic Failure"],"enrollment":89,"completionDate":"2029-12-31"},{"nctId":"NCT00004847","phase":"PHASE1","title":"Diagnosis of Pheochromocytoma","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2000-03-22","conditions":["Pheochromocytoma","Endocrine Disease","Endocrine Diseases"],"enrollment":3000,"completionDate":"2048-11-30"},{"nctId":"NCT07361796","phase":"NA","title":"The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-15","conditions":["Herpes Zoster","Pain","Postherpetic Neuralgia"],"enrollment":832,"completionDate":"2027-12-31"},{"nctId":"NCT07178366","phase":"NA","title":"Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-05-10","conditions":["Acute-on-Chronic Liver Failure (ACLF)"],"enrollment":56,"completionDate":"2027-10"},{"nctId":"NCT07077265","phase":"NA","title":"Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2025-08-01","conditions":["Spinal Aneshtesia","Hypotension After Spinal Anesthesia","Elderly (People Aged 65 or More)"],"enrollment":84,"completionDate":"2025-12-30"},{"nctId":"NCT07484217","phase":"PHASE3","title":"Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2026-02-23","conditions":["Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms"],"enrollment":508,"completionDate":"2028-12"},{"nctId":"NCT04901169","phase":"PHASE2,PHASE3","title":"Angiotensin II in Liver Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-06-28","conditions":["Liver Transplant; Complications","Vasoplegia"],"enrollment":50,"completionDate":"2027-03-18"},{"nctId":"NCT06083948","phase":"PHASE2,PHASE3","title":"Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-12-20","conditions":["Hypotension"],"enrollment":32,"completionDate":"2027-12-31"},{"nctId":"NCT07481097","phase":"NA","title":"Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04-01","conditions":["Acute Kidney Injury Due to Sepsis"],"enrollment":100,"completionDate":"2028-08"},{"nctId":"NCT07477392","phase":"NA","title":"Effect of Two Different Fluid Treatment Regimens on Ultrasonographic Upper Airway Measurements","status":"COMPLETED","sponsor":"Bozyaka Training and Research Hospital","startDate":"2023-03-01","conditions":["Goal-directed Fluid Theraphy","Upper Airway Ultrasonography"],"enrollment":145,"completionDate":"2025-10-01"},{"nctId":"NCT04569942","phase":"PHASE3","title":"Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2021-10-26","conditions":["Shock, Septic"],"enrollment":1000,"completionDate":"2026-11-03"},{"nctId":"NCT04789733","phase":"NA","title":"The GUARDIAN Pilot Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2021-04-27","conditions":["General Surgery"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":["Depressive Disorder, Major"],"enrollment":752,"completionDate":"2026-12-30"},{"nctId":"NCT06925646","phase":"","title":"Hand Perfusion and Pulse Oximetry Performance","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-09-01","conditions":["Oxygen Saturation"],"enrollment":20,"completionDate":"2028-10-01"},{"nctId":"NCT05841030","phase":"","title":"A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-28","conditions":["Depressive Disorder, Major"],"enrollment":545,"completionDate":"2026-03-13"},{"nctId":"NCT06802224","phase":"PHASE4","title":"The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-04-01","conditions":["Anesthesia","Surgery With General Anesthesia","Noncardiac Surgery","Hypotension During Surgery","Acute Kidney Injury (AKI)","Myocardial Injury After Noncardiac Surgery (MINS)","Vasopressor"],"enrollment":18000,"completionDate":"2028-07"},{"nctId":"NCT06709573","phase":"PHASE4","title":"Early Versus Late Adjunctive Vasopressin in Septic Shock","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-04-29","conditions":["Sepsis","Septic Shock"],"enrollment":300,"completionDate":"2026-05-01"},{"nctId":"NCT06746753","phase":"PHASE4","title":"Dysfunctional Renin-Angiotensin System in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-03","conditions":["Septic Shock"],"enrollment":78,"completionDate":"2028-08"},{"nctId":"NCT05851898","phase":"PHASE4","title":"Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-04-08","conditions":["Depression in Old Age","Fragility Fracture"],"enrollment":100,"completionDate":"2028-12"},{"nctId":"NCT07463222","phase":"","title":"Neuroendocrine Response in Pediatric Febrile Seizures","status":"NOT_YET_RECRUITING","sponsor":"Aydin Adnan Menderes University","startDate":"2026-03","conditions":["Febrile Convulsion","Neuroendocrine Stress Response","Fever"],"enrollment":120,"completionDate":"2027-03"},{"nctId":"NCT07455838","phase":"NA","title":"Impact of Virtual Reality Pelvic Floor Training on Postpartum Stress Urinary Incontinence","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-10","conditions":["Stress Urinary Incontinence"],"enrollment":50,"completionDate":"2026-05-31"},{"nctId":"NCT07326163","phase":"NA","title":"The Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Bilecik Seyh Edebali Universitesi","startDate":"2026-03-01","conditions":["Fibromyalgia","Aromatherapy","Cost"],"enrollment":175,"completionDate":"2027-01-01"},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":["Acute Aluminum Phosphide Poisoned Cases"],"enrollment":74,"completionDate":"2027-03"},{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":["Liver Cirrhosis With Diabetes"],"enrollment":64,"completionDate":"2025-10-01"},{"nctId":"NCT05939245","phase":"NA","title":"Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-07-24","conditions":["Acute Kidney Injury Due to Sepsis"],"enrollment":40,"completionDate":"2024-06-30"},{"nctId":"NCT07440069","phase":"PHASE4","title":"Analgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor","status":"RECRUITING","sponsor":"Universidad Nacional Autonoma de Honduras","startDate":"2026-02-15","conditions":["Labor Pain"],"enrollment":300,"completionDate":"2026-09-30"},{"nctId":"NCT05564741","phase":"PHASE4","title":"Acute Hip Fracture and Spinal Anaesthesia Injection Time","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2022-10-20","conditions":["Hypotension","Hip Fractures","Anesthesia"],"enrollment":84,"completionDate":"2024-12-31"},{"nctId":"NCT06426407","phase":"","title":"Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2025-10-01","conditions":["Shock, Septic"],"enrollment":2,"completionDate":"2026-02-01"},{"nctId":"NCT07418541","phase":"NA","title":"Early Co-Administration of Crystalloid Fluid and Norepinephrine for Preventing Acute Kidney Injury in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Universitas Sumatera Utara","startDate":"2026-04-23","conditions":["Septic Shock","Acute Kidney Injury"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":["Hot Flashes"],"enrollment":999,"completionDate":"2026-05-31"},{"nctId":"NCT03539614","phase":"PHASE3","title":"Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2018-06-04","conditions":["Posttraumatic Stress Disorder"],"enrollment":87,"completionDate":"2026-06-01"},{"nctId":"NCT05550532","phase":"PHASE3","title":"A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":["Depressive Disorder, Major","Anhedonia"],"enrollment":444,"completionDate":"2024-11-13"},{"nctId":"NCT06573970","phase":"PHASE4","title":"Atomoxetine and Executive Function in PTSD","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":["Posttraumatic Stress Disorder With Attention Defic"],"enrollment":160,"completionDate":"2029-09-28"},{"nctId":"NCT05179499","phase":"PHASE3","title":"Early Vasopressors in Sepsis","status":"RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-10-11","conditions":["Sepsis"],"enrollment":1006,"completionDate":"2027-10"},{"nctId":"NCT05972044","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2023-07-06","conditions":["ADHD"],"enrollment":516,"completionDate":"2025-03-14"},{"nctId":"NCT07398508","phase":"PHASE1,PHASE2","title":"Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease.","status":"RECRUITING","sponsor":"Stephen G. Kaler","startDate":"2026-06-01","conditions":["Menkes Disease"],"enrollment":6,"completionDate":"2030-06-30"},{"nctId":"NCT07322133","phase":"PHASE4","title":"Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":["Hypotension and Shock","Pulmonary Hypertension of the Newborn (PPHN)","Hypoxemic Respiratory Failure"],"enrollment":30,"completionDate":"2028-01-31"},{"nctId":"NCT07398417","phase":"PHASE3","title":"Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2026-01-14","conditions":["Fibromyalgia"],"enrollment":620,"completionDate":"2028-03"},{"nctId":"NCT06344442","phase":"PHASE3","title":"Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04-16","conditions":["Acute Kidney Injury Post Liver Transplantation"],"enrollment":304,"completionDate":"2027-05-16"},{"nctId":"NCT03828565","phase":"NA","title":"Decrease of Post-operative Complications by SCVO2 Monitoring an Optimisation of Cardiac Flow","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-03-01","conditions":["Cardiac Flow"],"enrollment":220,"completionDate":"2023-09-29"},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":["Septic Shock","Vasodilatory Shock"],"enrollment":40,"completionDate":"2025-03-12"},{"nctId":"NCT06532240","phase":"PHASE3","title":"Methylene Blue for the Treatment of Septic Shock","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2024-08-05","conditions":["Septic Shock"],"enrollment":88,"completionDate":"2025-10-24"},{"nctId":"NCT07384455","phase":"NA","title":"Use of Vasopressors in Hypotension Associated With Spinal Anaesthesia in Caesarean Sections","status":"COMPLETED","sponsor":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","startDate":"2021-01-03","conditions":["Caesarean Section"],"enrollment":70,"completionDate":"2021-08-31"},{"nctId":"NCT06880510","phase":"NA","title":"The Locus Coeruleus, Norepinephrine and Cognitive Aging","status":"RECRUITING","sponsor":"Cornell University","startDate":"2025-06-01","conditions":["Alzheimer Disease"],"enrollment":150,"completionDate":"2026-07-01"},{"nctId":"NCT06805851","phase":"","title":"Impact of Depression on Thermoregulation","status":"RECRUITING","sponsor":"Penn State University","startDate":"2025-03-01","conditions":["Depression","Selective Serotonin Reuptake Inhibitor"],"enrollment":64,"completionDate":"2027-01-30"},{"nctId":"NCT03207464","phase":"PHASE1,PHASE2","title":"Molecular Imaging of NET Using [C-11]MRB-PET in MS","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2017-10-10","conditions":["Multiple Sclerosis"],"enrollment":19,"completionDate":"2026-12-31"},{"nctId":"NCT07379710","phase":"PHASE4","title":"Norepinephrine With Ephedrine Versus Norepinephrine Alone During Spinal Anesthesia for Cesarean Delivery","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":["Incidence of Post-spinal Hypotension"],"enrollment":260,"completionDate":"2026-09"},{"nctId":"NCT06464510","phase":"PHASE3","title":"Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis","status":"RECRUITING","sponsor":"Hospital do Coracao","startDate":"2024-11-21","conditions":["Septic Shock"],"enrollment":2800,"completionDate":"2027-09"},{"nctId":"NCT04614168","phase":"NA","title":"Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2021-07-26","conditions":["Type 1 Diabetes","Type 1 Diabetes Mellitus With Hypoglycemia","Hypoglycemia","Hypoglycemia Unawareness","Glucagon Deficiency","Insulin Hypoglycemia"],"enrollment":24,"completionDate":"2025-12-26"},{"nctId":"NCT07363109","phase":"NA","title":"Comparison of the Efficacy of Continuous Metaraminol Infusion Versus Continuous Norepinephrine Infusion for the Prevention of Hypotension During Cesarean Section Under Spinal Anaesthesia. A Randomised Controlled Trial.","status":"NOT_YET_RECRUITING","sponsor":"Aretaieion University Hospital","startDate":"2026-02","conditions":["Hypotension After Spinal Anesthesia","Hypotension During Cesarean Delivery"],"enrollment":80,"completionDate":"2029-03"},{"nctId":"NCT07343206","phase":"NA","title":"Early Norepinephrine Administration and Rapid Dose Adjustment","status":"NOT_YET_RECRUITING","sponsor":"Siriraj Hospital","startDate":"2026-01","conditions":["Sepsis","Septic Shock"],"enrollment":600,"completionDate":"2028-03"},{"nctId":"NCT07327320","phase":"PHASE4","title":"Norepinephrine vs. Phenylephrine for Hypotension in Low-Dose Spinal Anesthesia for Cesarean Delivery","status":"COMPLETED","sponsor":"Tam Anh Research Institute","startDate":"2024-06-06","conditions":["Anesthesia","Spinal","Cesarean Section","Hypotension, Controlled"],"enrollment":100,"completionDate":"2025-10-04"},{"nctId":"NCT07354568","phase":"","title":"Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-10-20","conditions":["Cardiogenic Shock Acute","Bypass, Cardiopulmonary","Septic Shock","Mechanical Circulatory Support","Myocardial Infarction (MI)","Cardiogenic Shock Post Myocardial Infarction"],"enrollment":2500,"completionDate":"2027-06-01"},{"nctId":"NCT06633016","phase":"PHASE2","title":"Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)","status":"RECRUITING","sponsor":"Autobahn Therapeutics, Inc.","startDate":"2024-09-20","conditions":["Major Depressive Disorder"],"enrollment":230,"completionDate":"2026-06"},{"nctId":"NCT07209735","phase":"NA","title":"Effectiveness of the MINUTES Bundle for Initial 30-Minute Management of Undifferentiated Circulatory Shock in the Emergency Department","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-12-20","conditions":["Validation of Minute Bundle in Undifferntiated Shock"],"enrollment":202,"completionDate":"2027-10-20"},{"nctId":"NCT07339449","phase":"NA","title":"Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study","status":"RECRUITING","sponsor":"University Hospital Dubrava","startDate":"2025-08-01","conditions":["Major Abdominal Surgeries","Mechanical Ventilation"],"enrollment":100,"completionDate":"2027-06-30"},{"nctId":"NCT07063680","phase":"PHASE3","title":"Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2026-01","conditions":["Patients With Norepinephrine-refractory Vasoplegic Shock"],"enrollment":390,"completionDate":"2028-09"},{"nctId":"NCT07322419","phase":"PHASE4","title":"Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-01","conditions":["Cesarean Delivery","Spinal Anesthesia for Cesarean Section"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT06885268","phase":"PHASE3","title":"Noradrenaline Versus Standard Blood Pressure Management for Perioperative Hypotension in Non-cardiac Surgery","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2025-06-25","conditions":["Blood Pressure Management","Intraoperative Hypotension","Non-cardiac Surgery"],"enrollment":750,"completionDate":"2027-06-30"},{"nctId":"NCT02118467","phase":"PHASE4","title":"Vasoactive Drugs in Intensive Care Unit","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2014-05-15","conditions":["Shock"],"enrollment":836,"completionDate":"2026-12-01"},{"nctId":"NCT07330908","phase":"NA","title":"Different Norepinephrine Doses on Accuracy of Peripheral Perfusion Index in Predicting Tissue Perfusion in Septic Shock Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-10-30","conditions":["Septic Shock","Peripheral Perfusion Index"],"enrollment":80,"completionDate":"2025-03-30"},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":["Healthy","Major Depressive Disorder (MDD)"],"enrollment":204,"completionDate":"2027-02-01"},{"nctId":"NCT05997732","phase":"PHASE4","title":"Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2023-10-31","conditions":["Vasoconstriction","Vasodilation"],"enrollment":30,"completionDate":"2027-12-01"},{"nctId":"NCT06217939","phase":"NA","title":"Early Intravenous Hydrocortisone in Sepsis","status":"RECRUITING","sponsor":"Siriraj Hospital","startDate":"2024-06-25","conditions":["Sepsis Severe","Shock, Septic"],"enrollment":230,"completionDate":"2026-09"},{"nctId":"NCT04961190","phase":"PHASE4","title":"A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-05-25","conditions":["Posttraumatic Stress Disorder"],"enrollment":302,"completionDate":"2026-07-15"},{"nctId":"NCT04844801","phase":"NA","title":"Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-11-09","conditions":["Supraventricular Arrhythmia","Septic Shock"],"enrollment":240,"completionDate":"2026-03"},{"nctId":"NCT07313605","phase":"PHASE1,PHASE2","title":"POCUS-Guided Esmolol in Septic Shock: A Pilot RCT","status":"NOT_YET_RECRUITING","sponsor":"John Basmaji","startDate":"2026-01-15","conditions":["Septic Shock"],"enrollment":100,"completionDate":"2028-04-15"},{"nctId":"NCT06360419","phase":"PHASE3","title":"Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-03-18","conditions":["Major Depressive Disorder"],"enrollment":346,"completionDate":"2025-03-26"},{"nctId":"NCT06053398","phase":"EARLY_PHASE1","title":"Vasopressor Outcomes in Spine Surgery","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-11-21","conditions":["Hypotension"],"enrollment":101,"completionDate":"2024-12-30"},{"nctId":"NCT06921473","phase":"PHASE4","title":"Effect of Ephedrine vs. Norepinephrine on Prevention of Fetal Acidosis During Cesarean Section Under Spinal Anesthesia","status":"COMPLETED","sponsor":"mehmet özkılıç","startDate":"2025-09-01","conditions":["Cesarean Delivery Affecting Newborn","Acidosis","Maternal Hypotension","Spinal Aneshtesia"],"enrollment":102,"completionDate":"2025-12-15"},{"nctId":"NCT07305922","phase":"","title":"Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2025-12-01","conditions":["Subarachnoid Aneurysm Hemorrhage","Cerebral Vasospasm After Subarachnoid Hemorrhage"],"enrollment":200,"completionDate":"2030-12-31"},{"nctId":"NCT06952907","phase":"NA","title":"Femoral Versus Radial Invasive Arterial Pressure Monitoring in Cardiac Surgery Patients","status":"RECRUITING","sponsor":"Guillaume BESCH","startDate":"2025-06-15","conditions":["Vasoplegia Syndrome","Vasoplegia","Cardiac Surgical Procedures","Arterial Pressure","Hypotension During Surgery","Hypotension Postprocedural","Norepinephrine"],"enrollment":340,"completionDate":"2027-08-01"},{"nctId":"NCT07296029","phase":"PHASE1,PHASE2","title":"CONFOCAL-2 Interventional Pilot Study","status":"COMPLETED","sponsor":"Queen's University","startDate":"2022-07-29","conditions":["Critical Illness","Respiratory Failure","Shock","Delirium"],"enrollment":16,"completionDate":"2025-02-08"},{"nctId":"NCT06058897","phase":"NA","title":"Magnetic Resonance Imaging (MRI) and Eye-tracking Predictive Markers of Cognitive Ageing.","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2024-03-22","conditions":["Aging"],"enrollment":100,"completionDate":"2028-03-22"},{"nctId":"NCT07167316","phase":"PHASE1","title":"The Role of the LC-NA System in Experimental Sleep Fragmentation","status":"NOT_YET_RECRUITING","sponsor":"Hans-Peter Landolt","startDate":"2026-01-05","conditions":["The Role of the LC-NA System in Sleep Regulation"],"enrollment":42,"completionDate":"2026-10-01"},{"nctId":"NCT05568160","phase":"PHASE3","title":"Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2023-01-02","conditions":["Scheduled Cardiac Surgery With Extracorporeal Circulation","Vasoplegic Syndrome"],"enrollment":840,"completionDate":"2026-03"},{"nctId":"NCT07004686","phase":"NA","title":"Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients","status":"RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-06-28","conditions":["Opioid Use"],"enrollment":112,"completionDate":"2026-05-30"},{"nctId":"NCT04789330","phase":"PHASE4","title":"Norepinephrine vs Phenylephrine During General Anesthesia","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-07-01","conditions":["Anesthesia","Surgery","Hypotension"],"enrollment":3626,"completionDate":"2022-04-01"},{"nctId":"NCT06631482","phase":"NA","title":"Comparison Bewteen Intraoperative HPI vs. High Mean Arterial Pressure Threshold","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-16","conditions":["Hypotension During Surgery"],"enrollment":100,"completionDate":"2026-05-31"},{"nctId":"NCT05032261","phase":"","title":"ICU Norepinephrine Load","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-09-01","conditions":["Circulatory Collapse and Shock"],"enrollment":100,"completionDate":"2024-12-31"},{"nctId":"NCT02783430","phase":"PHASE2,PHASE3","title":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2016-09-08","conditions":["Depression"],"enrollment":42,"completionDate":"2024-03-08"},{"nctId":"NCT07286643","phase":"NA","title":"Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":["Cirrhosis, Liver","Cirrhotic Cardiomyopathy","Septic Shock"],"enrollment":140,"completionDate":"2028-12-30"},{"nctId":"NCT07255378","phase":"","title":"Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication","status":"RECRUITING","sponsor":"Jamil Cedeño Mora","startDate":"2025-10-01","conditions":["Septic Shock"],"enrollment":1200,"completionDate":"2028-01-01"},{"nctId":"NCT07259655","phase":"PHASE4","title":"Management of Post-Induction Hypotension in Emergency Abdominal Surgery","status":"TERMINATED","sponsor":"Hopital Charles Nicolle","startDate":"2025-03-06","conditions":["Post-induction Hypotension"],"enrollment":100,"completionDate":"2025-05-06"},{"nctId":"NCT01426529","phase":"PHASE1","title":"Caveolin-1 and Vascular Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2010-10-01","conditions":["Hypertension","Insulin Resistance"],"enrollment":120,"completionDate":"2026-10-15"},{"nctId":"NCT06462313","phase":"NA","title":"Dobutamine for Management of Surgical Patients With Septic Shock","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-18","conditions":["Patients With Septic Shock","Surgical Patients","General Anesthesia"],"enrollment":584,"completionDate":"2025-11-15"},{"nctId":"NCT05276596","phase":"PHASE3","title":"Evaluation of the Early Use of Norepinephrine in Major Abdominal Surgery on Postoperative Organ Dysfunction","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-11-17","conditions":["Norepinephrine","Hypotension","Anesthesiology","Major Abdominal Surgery"],"enrollment":500,"completionDate":"2025-11-29"},{"nctId":"NCT07163858","phase":"NA","title":"Postural Mobilization Compared to Noradrenaline Only in Off-Pump CABG Surgery","status":"RECRUITING","sponsor":"Infirmerie Protestante de Lyon","startDate":"2025-10-06","conditions":["Coronary Artery Disease With Need for Bypass Surgery","Coronary Artery Disease(CAD)","Coronary Artery Bypass","Off Pump Coronary Artery Bypass Graft","Off Pump Coronary Artery Bypass Surgery","Hemodynamic Management","Hemodynamic Optimization","Noradrenaline"],"enrollment":50,"completionDate":"2027-08"},{"nctId":"NCT07258875","phase":"NA","title":"Effect of VExUS Ultrasound Protocol (Venous Excess Ultrasound) on Perioperative Fluid Management, on the Incidence of Postoperative Pulmonary Complications and Postoperative Acute Kidney Injury in Patients Undergoing Thoracic Surgery","status":"RECRUITING","sponsor":"University of Crete","startDate":"2024-11-27","conditions":["Thoracic Surgery With One-lung Ventilation","VExUS","Fluid Management","Acute Kidney Injury","Postoperative Pulmonary Complications (PPCs)"],"enrollment":230,"completionDate":"2029-11-01"},{"nctId":"NCT06295562","phase":"PHASE4","title":"Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2024-11-05","conditions":["Obstructive Sleep Apnea of Adult"],"enrollment":45,"completionDate":"2025-10-22"},{"nctId":"NCT04403165","phase":"NA","title":"Locus-coeruleus Function in Normal Elderly and AD Risk","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-06","conditions":["Alzheimer Disease"],"enrollment":30,"completionDate":"2024-03-26"},{"nctId":"NCT06520982","phase":"EARLY_PHASE1","title":"Early Neurovascular Adaptations in Aging Women","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2024-09-20","conditions":["Women","Sympathetic Nervous System","Aging","Blood Flow"],"enrollment":64,"completionDate":"2028-06-30"},{"nctId":"NCT06878976","phase":"PHASE3","title":"Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"Axsome Therapeutics, Inc.","startDate":"2025-02-20","conditions":["Binge-Eating Disorder"],"enrollment":300,"completionDate":"2026-12"},{"nctId":"NCT06568367","phase":"PHASE3","title":"Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-08-01","conditions":["Excessive Sleepiness","Shift-work Disorder"],"enrollment":520,"completionDate":"2026-12"},{"nctId":"NCT06413433","phase":"PHASE3","title":"Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-04-26","conditions":["Binge-Eating Disorder"],"enrollment":450,"completionDate":"2025-12"},{"nctId":"NCT07239791","phase":"NA","title":"Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE)","status":"RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2025-11-18","conditions":["Role of the Noradrenergic System in the Regulation of Learning Dynamics","No Disease or Condition is Being Studied"],"enrollment":160,"completionDate":"2027-12"},{"nctId":"NCT07238465","phase":"PHASE3","title":"Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12","conditions":["Down Syndrome","Autonomic Dysfunction"],"enrollment":200,"completionDate":"2029-12"},{"nctId":"NCT02473263","phase":"PHASE3","title":"Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-09","conditions":["Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit"],"enrollment":398,"completionDate":"2019-02-09"},{"nctId":"NCT02116140","phase":"NA","title":"ASV Effects on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2012-07","conditions":["Heart Failure","Obstructive Sleep Apnea","Central Sleep Apnea"],"enrollment":60,"completionDate":"2026-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Solution","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"NOREPINEPHRINE BITARTRATE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Norepinephrine Bitartrate"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Norepinephrine bitartrate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Norepinephrine Bitartrate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"NOREPINEPHRINE BITARTRATE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Norepinephrine Bitartrate"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"NOREPINEPHRINE BITARTRATE"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Norepinephrine Bitartrate"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Norepinephrine bitartrate"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"LEVOPHED"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"LEVOPHED(R) NOREPINEPHRINE BITARTRATE"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Levophed"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"NOREPINEPHRINE BITARTRATE"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Norepinephrine Bitartrate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147945","MMSL":"2706","NDDF":"001777","UNII":"X4W3ENH1CV","VUID":"4019859","CHEBI":"CHEBI:33569","VANDF":"4018242","INN_ID":"33","RXNORM":"7508","UMLSCUI":"C0028351","chemblId":"CHEMBL432","ChEMBL_ID":"CHEMBL1434513","KEGG_DRUG":"D00076","DRUGBANK_ID":"DB00368","PDB_CHEM_ID":" LT4","PUBCHEM_CID":"439260","SNOMEDCT_US":"111130009","IUPHAR_LIGAND_ID":"484","SECONDARY_CAS_RN":"108341-18-0","MESH_DESCRIPTOR_UI":"D009638"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","company":"Hospira, Inc.","brandName":"LEVOPHED","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1950-","companyName":"Pfizer","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"3%"},"publicationCount":65037,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01CA03","allCodes":["C01CA03"]},"biosimilarFilings":[],"originalDeveloper":"Hospira","recentPublications":[{"date":"2026 Apr","pmid":"41906544","title":"Understanding Atomoxetine Exposure Variability in Children and Adolescents With ADHD Through Population Pharmacokinetics.","journal":"Journal of clinical pharmacology"},{"date":"2026 Mar 29","pmid":"41905899","title":"Emerging mechanisms of ILC2-neuronal crosstalk across the body.","journal":"Immunology and cell biology"},{"date":"2026 Mar 23","pmid":"41905254","title":"Stress and sleep: Novel insights into stress-related sleep disorders from EEG features to neural circuitry.","journal":"Sleep medicine"},{"date":"2026 Mar 28","pmid":"41904178","title":"Human narcolepsy is linked to degeneration of both locus coeruleus and hypocretin neurons.","journal":"Nature communications"},{"date":"2026 Mar 28","pmid":"41903111","title":"Mechanisms of norepinephrine induced Ca(2+) responses in perivascular adipose tissue.","journal":"American journal of physiology. Endocrinology and metabolism"}],"companionDiagnostics":[],"genericManufacturers":19,"_genericFilersChecked":true,"genericManufacturerList":["Amneal","Anthea Pharma","Aspiro","Baxter Hlthcare Corp","Biocon Pharma","Breckenridge","Caplin","Fresenius Kabi Usa","Gland","Hikma","Meitheal","Metrics Pharm","Msn","Mylan Labs Ltd","Rising","Sagent","Sandoz","Sun Pharm","Zydus Pharms"],"status":"approved","companyName":"Hospira","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1950","aiSummary":"","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1950-07-13T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-08-31T00:00:00.000Z","mah":"MEITHEAL","brand_name_local":null,"application_number":"ANDA040455"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-10-04T00:00:00.000Z","mah":"MYLAN LABS LTD","brand_name_local":null,"application_number":"ANDA211242"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-12-17T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA210839"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-06T00:00:00.000Z","mah":"LONG GROVE PHARMS","brand_name_local":null,"application_number":"NDA214628"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-09-15T00:00:00.000Z","mah":"CAPLIN","brand_name_local":null,"application_number":"ANDA217575"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:00:02.526212+00:00","fieldsConflicting":13,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}